UCB SA (OTCMKTS:UCBJY) Short Interest Update

UCB SA (OTCMKTS:UCBJY) was the recipient of a large decline in short interest during the month of July. As of July 15th, there was short interest totaling 2,283 shares, a decline of 60.4% from the June 30th total of 5,769 shares. Currently, 0.0% of the company’s stock are short sold. Based on an average daily volume of 58,706 shares, the days-to-cover ratio is presently 0.0 days.

UCB Price Performance

OTCMKTS UCBJY opened at $139.01 on Monday. UCB has a one year low of $103.43 and a one year high of $168.76. The stock has a 50-day moving average of $143.75 and a 200 day moving average of $147.85. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Jefferies Financial Group raised shares of UCB to a “moderate sell” rating in a report on Monday, June 22nd. Barclays cut shares of UCB from a “strong-buy” rating to a “hold” rating in a report on Monday, June 15th. Finally, Zacks Research upgraded shares of UCB from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, UCB has a consensus rating of “Hold”.

UCB Company Profile

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.